JP2021533204A5 - - Google Patents
Info
- Publication number
- JP2021533204A5 JP2021533204A5 JP2021529521A JP2021529521A JP2021533204A5 JP 2021533204 A5 JP2021533204 A5 JP 2021533204A5 JP 2021529521 A JP2021529521 A JP 2021529521A JP 2021529521 A JP2021529521 A JP 2021529521A JP 2021533204 A5 JP2021533204 A5 JP 2021533204A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- btn3a
- pharmaceutical composition
- seq
- isolated anti
- Prior art date
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023204480A JP7825605B2 (ja) | 2018-08-01 | 2023-12-04 | 抗ｂｔｎ３ａ抗体及びがん又は感染性障害の処置におけるその使用 |
| JP2025160594A JP2026016397A (ja) | 2018-08-01 | 2025-09-26 | 抗ｂｔｎ３ａ抗体及びがん又は感染性障害の処置におけるその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306050 | 2018-08-01 | ||
| EP18306050.8 | 2018-08-01 | ||
| EP19153992 | 2019-01-28 | ||
| EP19153992.3 | 2019-01-28 | ||
| PCT/EP2019/070693 WO2020025703A1 (en) | 2018-08-01 | 2019-07-31 | Anti-btn3a antibodies and their use in treating cancer or infectious disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204480A Division JP7825605B2 (ja) | 2018-08-01 | 2023-12-04 | 抗ｂｔｎ３ａ抗体及びがん又は感染性障害の処置におけるその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021533204A JP2021533204A (ja) | 2021-12-02 |
| JP2021533204A5 true JP2021533204A5 (https=) | 2022-08-05 |
| JPWO2020025703A5 JPWO2020025703A5 (https=) | 2022-08-05 |
| JP7401166B2 JP7401166B2 (ja) | 2023-12-19 |
Family
ID=67470408
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529521A Active JP7401166B2 (ja) | 2018-08-01 | 2019-07-31 | 抗ｂｔｎ３ａ抗体及びがん又は感染性障害の処置におけるその使用 |
| JP2023204480A Active JP7825605B2 (ja) | 2018-08-01 | 2023-12-04 | 抗ｂｔｎ３ａ抗体及びがん又は感染性障害の処置におけるその使用 |
| JP2025160594A Pending JP2026016397A (ja) | 2018-08-01 | 2025-09-26 | 抗ｂｔｎ３ａ抗体及びがん又は感染性障害の処置におけるその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204480A Active JP7825605B2 (ja) | 2018-08-01 | 2023-12-04 | 抗ｂｔｎ３ａ抗体及びがん又は感染性障害の処置におけるその使用 |
| JP2025160594A Pending JP2026016397A (ja) | 2018-08-01 | 2025-09-26 | 抗ｂｔｎ３ａ抗体及びがん又は感染性障害の処置におけるその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11987631B2 (https=) |
| EP (2) | EP4650007A3 (https=) |
| JP (3) | JP7401166B2 (https=) |
| KR (1) | KR102949202B1 (https=) |
| CN (2) | CN118459590A (https=) |
| AU (2) | AU2019312831B2 (https=) |
| BR (1) | BR112021001776A2 (https=) |
| CA (2) | CA3275403A1 (https=) |
| CL (1) | CL2021000258A1 (https=) |
| DK (1) | DK3830119T3 (https=) |
| ES (1) | ES3060430T3 (https=) |
| FI (1) | FI3830119T3 (https=) |
| HR (1) | HRP20260034T1 (https=) |
| IL (1) | IL280563B2 (https=) |
| LT (1) | LT3830119T (https=) |
| MX (1) | MX2021001268A (https=) |
| RS (1) | RS67711B1 (https=) |
| SG (1) | SG11202101038SA (https=) |
| SI (1) | SI3830119T1 (https=) |
| SM (1) | SMT202600072T1 (https=) |
| WO (1) | WO2020025703A1 (https=) |
| ZA (1) | ZA202100819B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230183346A1 (en) * | 2016-02-26 | 2023-06-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies having specificity for btla and uses thereof |
| HRP20260034T1 (hr) * | 2018-08-01 | 2026-02-27 | Imcheck Therapeutics | Anti-btn3a antitijela i njihova upotreba u liječenju raka ili infektivnih poremećaja |
| AU2022293581A1 (en) * | 2021-06-18 | 2024-01-25 | Therini Bio, Inc. | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE |
| TW202313695A (zh) | 2021-09-15 | 2023-04-01 | 法商感應檢查療法公司 | 抗ｂｔｎ３ａ抗體在製備用於治療腫瘤的藥物的用途 |
| WO2023052541A1 (en) | 2021-09-30 | 2023-04-06 | Imcheck Therapeutics | Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy |
| JP2024539893A (ja) | 2021-10-27 | 2024-10-31 | イムチェック セラピューティクス エスエーエス | 感染性障害を治療する方法で使用するためのブチロフィリン（ｂｔｎ）３ａ活性化抗体 |
| KR20240149438A (ko) | 2022-02-27 | 2024-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | Cd277 및 종양-항원에 대한 이중특이적 항체 |
| WO2024074498A1 (en) | 2022-10-04 | 2024-04-11 | Imcheck Therapeutics | Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer |
| JP2026506893A (ja) | 2023-02-23 | 2026-02-27 | イムチェック セラピューティクス エスエーエス | Ｂｔｎ３ａ活性化抗体と免役チェックポイント阻害剤の併用 |
| TW202506731A (zh) | 2023-04-27 | 2025-02-16 | 法商感應檢查療法公司 | 治療多重抗藥性細菌感染之方法 |
| WO2024261239A1 (en) | 2023-06-23 | 2024-12-26 | Imcheck Therapeutics | Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis |
| WO2025031287A1 (zh) * | 2023-08-04 | 2025-02-13 | 江苏恒瑞医药股份有限公司 | Btn3a结合蛋白及其医药用途 |
| WO2025223116A1 (en) * | 2024-04-24 | 2025-10-30 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-btn3a antibodies and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CN101370830A (zh) * | 2005-09-26 | 2009-02-18 | 米德列斯公司 | 抗cd70的人单克隆抗体 |
| US20120064096A1 (en) | 2009-03-17 | 2012-03-15 | Universite De La Mediterranee | BTLA Antibodies and Uses Thereof |
| CN102762593B (zh) | 2009-07-31 | 2015-05-20 | 梅达雷克斯有限责任公司 | 抗btla的完全人抗体 |
| AU2010290844B2 (en) * | 2009-09-06 | 2015-04-09 | Protab Ltd. | Humanized antibodies specific for HSP65-derived peptide-6 methods and uses thereof |
| US8940300B2 (en) * | 2010-07-15 | 2015-01-27 | Adheron Therapeutics, Inc. | Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods |
| WO2012080769A1 (en) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd277 antibodies and uses thereof |
| US20150353643A1 (en) * | 2013-09-24 | 2015-12-10 | Universite De La Mediterranee - Aix-Marseille Ii | Anti-cd277 antibodies and uses thereof |
| TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗－ｔａｕ抗體 |
| WO2016081518A2 (en) * | 2014-11-17 | 2016-05-26 | Adicet Bio, Inc. | Engineered gamma delta t-cells |
| US20230183346A1 (en) | 2016-02-26 | 2023-06-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies having specificity for btla and uses thereof |
| HRP20260034T1 (hr) * | 2018-08-01 | 2026-02-27 | Imcheck Therapeutics | Anti-btn3a antitijela i njihova upotreba u liječenju raka ili infektivnih poremećaja |
| TW202313695A (zh) * | 2021-09-15 | 2023-04-01 | 法商感應檢查療法公司 | 抗ｂｔｎ３ａ抗體在製備用於治療腫瘤的藥物的用途 |
-
2019
- 2019-07-31 HR HRP20260034TT patent/HRP20260034T1/hr unknown
- 2019-07-31 LT LTEPPCT/EP2019/070693T patent/LT3830119T/lt unknown
- 2019-07-31 KR KR1020217006171A patent/KR102949202B1/ko active Active
- 2019-07-31 MX MX2021001268A patent/MX2021001268A/es unknown
- 2019-07-31 SG SG11202101038SA patent/SG11202101038SA/en unknown
- 2019-07-31 CN CN202410579882.5A patent/CN118459590A/zh active Pending
- 2019-07-31 JP JP2021529521A patent/JP7401166B2/ja active Active
- 2019-07-31 IL IL280563A patent/IL280563B2/en unknown
- 2019-07-31 AU AU2019312831A patent/AU2019312831B2/en active Active
- 2019-07-31 FI FIEP19745618.9T patent/FI3830119T3/fi active
- 2019-07-31 CA CA3275403A patent/CA3275403A1/en active Pending
- 2019-07-31 SI SI201931018T patent/SI3830119T1/sl unknown
- 2019-07-31 SM SM20260072T patent/SMT202600072T1/it unknown
- 2019-07-31 CA CA3107933A patent/CA3107933A1/en active Pending
- 2019-07-31 EP EP25206189.0A patent/EP4650007A3/en active Pending
- 2019-07-31 WO PCT/EP2019/070693 patent/WO2020025703A1/en not_active Ceased
- 2019-07-31 BR BR112021001776-3A patent/BR112021001776A2/pt unknown
- 2019-07-31 ES ES19745618T patent/ES3060430T3/es active Active
- 2019-07-31 RS RS20260132A patent/RS67711B1/sr unknown
- 2019-07-31 US US17/264,507 patent/US11987631B2/en active Active
- 2019-07-31 EP EP19745618.9A patent/EP3830119B1/en active Active
- 2019-07-31 DK DK19745618.9T patent/DK3830119T3/da active
- 2019-07-31 CN CN201980051396.3A patent/CN113286819B/zh active Active
-
2021
- 2021-01-29 CL CL2021000258A patent/CL2021000258A1/es unknown
- 2021-02-05 ZA ZA2021/00819A patent/ZA202100819B/en unknown
-
2022
- 2022-09-26 US US17/935,154 patent/US20230272080A1/en not_active Abandoned
-
2023
- 2023-06-01 US US18/327,127 patent/US11945871B2/en active Active
- 2023-12-04 JP JP2023204480A patent/JP7825605B2/ja active Active
-
2025
- 2025-09-26 JP JP2025160594A patent/JP2026016397A/ja active Pending
- 2025-10-29 AU AU2025259841A patent/AU2025259841A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533204A5 (https=) | ||
| CN103619878B (zh) | 结合血清白蛋白的蛋白 | |
| JP2023011661A (ja) | 標的化キメラタンパク質及びその使用 | |
| EP3119806B1 (en) | Il-21 antibodies | |
| TWI436776B (zh) | Ｆｇｆ２１突變體及其用途 | |
| US20160175458A1 (en) | Single chain fc fusion proteins | |
| JPH03501330A (ja) | カケクチンと反応するモノクロナール抗体 | |
| RU2651776C2 (ru) | Биспецифические антитела против cd3*cd19 | |
| CN103079586B (zh) | G‑csf二聚体在治疗嗜中性粒细胞减少症中的应用 | |
| CA2663042A1 (en) | Serum albumin binding proteins with long half-lives | |
| FI3830119T3 (fi) | Anti-btn3a-vasta-aineita ja niiden käyttö syövän tai infektiosairauksien hoitamisessa | |
| JP7702445B2 (ja) | 免疫調節融合タンパク質 | |
| JP6192862B2 (ja) | Ｆｃ融合高親和性ＩｇＥ受容体α鎖 | |
| TW201520226A (zh) | 泛－ｅｌｒ＋ｃｘｃ趨化因子抗體 | |
| JPWO2020025703A5 (https=) | ||
| TW202035459A (zh) | 抗人類Fn14抗體 | |
| WO2019148405A1 (zh) | IL-4Rα抗体及其用途 | |
| JP2017524675A5 (https=) | ||
| JP2023542049A (ja) | インターロイキン－２ムテイン及びその使用 | |
| JP7606173B2 (ja) | Ｉ型インターフェロンの中和型Ｆｃ融合タンパク質及びその使用 | |
| RU2021104977A (ru) | Антитела против btn3a и их применение при лечении рака или инфекционных заболеваний | |
| CN1291998C (zh) | Nkg2d受体的配体及其应用 | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| WO2025256479A1 (zh) | 一种融合蛋白及其用途 | |
| HK40103504A (zh) | 工程化抗il-2抗体 |